情報リーフレット
1
SUMMARY OF PRODUCT CHARACTERISTICS
2
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin 10 mg capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains:
Active substance
Pimobendan
10 mg
Excipients
Titanium dioxide (E171)
1.920 mg
Red iron oxide (E172)
0.154 mg
Black iron oxide (E172)
0.031 mg
Erythrosin (E127)
0.077 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Capsule, hard.
Oblong hard gelatine capsule with a pink opaque cap and a white opaque body.
4.
CLINICAL PARTICULARS
4.1.
TARGET SPECIES
Dogs
4.2.
INDICATIONS FOR USE , SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular
insufficiency (mitral and/or tricuspid regurgitation).
4.3.
CONTRAINDICATIONS
Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of
cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis).
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
4.4.
SPECIAL WARNINGS
In diabetic animals, glucose levels have to be strictly controlled.
Absorption of this product is modified when administered with food. Therefore, the optimum efficacy is
granted when the stomach is empty. The product should be given one hour before feeding.
3
4.5.
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS F
完全なドキュメントを読む
製品の特徴
1
SUMMARY OF PRODUCT CHARACTERISTICS
2
SUMMARY OF PRODUCT CHARACTERISTICS
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin 10 mg capsules
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each capsule contains:
Active substance
Pimobendan
10 mg
Excipients
Titanium dioxide (E171)
1.920 mg
Red iron oxide (E172)
0.154 mg
Black iron oxide (E172)
0.031 mg
Erythrosin (E127)
0.077 mg
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Capsule, hard.
Oblong hard gelatine capsule with a pink opaque cap and a white opaque body.
4.
CLINICAL PARTICULARS
4.1.
TARGET SPECIES
Dogs
4.2.
INDICATIONS FOR USE , SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or valvular
insufficiency (mitral and/or tricuspid regurgitation).
4.3.
CONTRAINDICATIONS
Do not use in cases of hypertrophic cardiomyopathies or clinical conditions where an augmentation of
cardiac output is not possible for functional or anatomical reasons (e.g. aortic stenosis).
Do not use in case of hypersensitivity to the active substance or to any of the excipients.
4.4.
SPECIAL WARNINGS
In diabetic animals, glucose levels have to be strictly controlled.
Absorption of this product is modified when administered with food. Therefore, the optimum efficacy is
granted when the stomach is empty. The product should be given one hour before feeding.
3
4.5.
SPECIAL PRECAUTIONS FOR USE
SPECIAL PRECAUTIONS F
完全なドキュメントを読む
情報リーフレット 